Please login to the form below

Not currently logged in
Email:
Password:

Prevail Therapeutics adds to its board of directors

Francois Nader joins the biotech

Francois NaderPrevail Therapeutics, a biotechnology company focused on the development of gene therapies for patients with neurodegenerative diseases, has strengthened its board of directors with the addition of Francois Nader.

From 2008-2015 Nader was president and chief executive officer of NPS Pharma, until Shire acquired the company for $5.2bn.

Nader said: “I am honoured to join the board of Prevail Therapeutics.

“The Prevail team has already made great progress in developing potential treatments for Parkinson’s disease and other neurodegenerative diseases, and I look forward to partnering with the team to help accelerate important therapeutic advances for patients with these devastating illnesses.”

Before his time at NPS, Nader was a venture partner at Care Capital and he also previously served on the North America leadership team of Aventis and its predecessor companies, holding a number of executive positions including senior vice president of integrated healthcare markets.

Commenting on the appointments, Asa Abeliovich, founder and chief executive officer at Prevail, said: “Francois’ leadership and proven track record in building and operating biotech companies will be invaluable as we advance our pipeline of gene therapy programmes toward the clinic.”

31st May 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

R&D protocol amendments
Rethinking trials: the pros and cons of protocol amendments
Protocol amendments occur often and can be beneficial, but the steps involved can be complex...
Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...

Infographics